Merck KGaA announces €300 million investment in South Korea for new Bioprocessing Production Center

New Delhi: Merck KGaA Darmstadt Germany has unveiled its largest investment in Asia with the groundbreaking ceremony for a €300 million Bioprocessing Production Center in Daejeon, South Korea.

This state-of-the-art facility is set to significantly boost the biotech and pharmaceutical sectors by manufacturing vaccines, cell and gene therapies, and protein-based therapies.

The investment is projected to create approximately 300 new jobs, catering to the increasing global demand for essential drugs and advanced therapies.

The ceremony was attended by prominent figures from Merck, including Matthias Heinzel, CEO of the Life Science business at Merck; Karen Madden, Chief Technology Officer of the Life Science business; Sebastián Arana, Head of Process Solutions, Life Science business; and Ivan Donzelot, Head of Integrated Supply Chain Operations. They were joined by key Korean officials such as Trade Minister Cheong Inkyo, Daejeon Mayor Lee Jang Woo, and Ambassador Georg Schmidt, along with other dignitaries and partners.

The new Bioprocessing Production Center in Asia reinforces Merck’s dedication to supporting the global healthcare landscape through advanced manufacturing and innovation.